Clinical data
Routes of
ATC code None
Legal status
Legal status
  • Experimental
Pharmacokinetic data
Biological half-life 24.3 hours[1]
CAS Number 915133-65-2
PubChem (CID) 11962616
ChemSpider 10136846 YesY
KEGG DG01232 YesY
Chemical and physical data
Formula C25H30F2N2O4
Molar mass 403.898 g/mol
3D model (Jmol) Interactive image

Abediterol (INN)[2] (codenamed AZD-0548, LAS 100977) is a novel, once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.[3][4]

It acts as a β2 adrenergic agonist[5][6] and is classified as an ultra-long-acting β2 agonist (ultra-LABA).[7]

Its coformulation with mometasone furoate is also in Phase II clinical trials.[8]


  1. Timmer, Wolfgang; Massana, Eric; Jimenez, Eulalia; Seoane, Beatriz; de Miquel, Gonzalo; Ruiz, Sandrine (December 2014). "First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Abediterol (LAS100977), a Novel Long-Acting β2-agonist". The Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355.
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.
  3. Product development pipeline, Almirall
  4. "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.
  5. WO 2006122788
  6. WO 2010094484
  7. Beier, J; Fuhr, R; Massana, E; Jiménez, E; Seoane, B; de Miquel, G; Ruiz, S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–1429. doi:10.1016/j.rmed.2014.08.005. PMID 25256258. Retrieved 25 March 2016.
  8. "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

This article is issued from Wikipedia - version of the 6/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.